Molecular diagnosis of lung cancer: An overview of recent developments

Acta Biomedica de l'Ateneo Parmense

Volumn 79, Issue SUPPL. 1, 2008, Pages 11-23

  Mutti, Antonio ^a,b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Biomarkers; Lung cancer; Occupational diseases; Screening; Smoking

Indexed keywords

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; EXHALATION; LABORATORY DIAGNOSIS; LUNG CANCER; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; THORAX RADIOGRAPHY;

BIOLOGICAL MARKERS; FORECASTING; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; RISK FACTORS;

EID: 48749127880     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: Evidence and practice in Europe 2008. Eur J Cancer 2008; In press.
2. WHO. Lung Cancer Report. World Health Organization, Geneve, Switzerland, 2003.
3. Ciatto S. Current cancer profiles of the Italian regions: should cancer incidence be monitored at a national level? Tumori 2007; 93: 529-31.
4. Nagai K, Yoshida J, Nishimura M. Postoperative mortality in lung cancer patients. Ann Thorac Cardiovasc Surg 2007; 13: 373-7.
5. Albrand G, Biron E, Boucot I, et al. [Lung cancer in the elderly subject]. Rev Mal Respir 2007; 24: 703-23.
6. Veglia F, Vineis P, Overvad K, et al. Occupational exposures, environmental tobacco smoke, and lung cancer. Epidemiology 2007; 18: 769-75.
7. Zhou W, Heist RS, Liu G, et al. Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients. Clin Cancer Res 2006; 12: 7187-93.
8. Boffetta P. Human cancer from environmental pollutants: the epidemiological evidence. Mutat Res 2006; 608: 157-62.
9. Ong EK, Glantz SA. Tobacco industry efforts subverting International Agency for Research on Cancer's second-hand smoke study. Lancet 2000; 355: 1253-9.
10. Calafat AM, Polzin GM, Saylor J, Richter P, Ashley DL, Watson CH. Determination of tar, nicotine, and carbon monoxide yields in the mainstream smoke of selected international cigarettes. Tob Control 2004; 13: 45-51.
11. Thompson RE, Nelson DF, Popkin JH, Popkin Z. Case-control study of lung cancer risk from residential radon exposure in Worcester county, Massachusetts. Health Phys 2008; 94: 228-41.
12. Giovino GA. The tobacco epidemic in the United States. Am J Prev Med 2007; 33: S318-26.
13. Cowling DW, Bond P. Smoke-free laws and bar revenues in California - the last call. Health Econ 2005; 14: 1273-81.
14. Knoke JD, Burns DM, Thun MJ. The change in excess risk of lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control 2008; 19: 207-19.
15. Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 2008; 13: 309-19.
16. Chataigner O, Fadel E, Yildizeli B, et al. Factors affecting early and long-term outcomes after completion pneumonectomy. Eur J Cardiothorac Surg 2008; In press.
17. Patz EF, Jr., Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000; 343: 1627-33.
18. Weiss W, Boucot KR, Seidman H. The Philadelphia Pulmonary Neoplasms Research Project. Clin Chest Med 1982; 3: 243-56.
19. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? Lung Cancer 2002; 37: 271-6.
20. Hayata Y, Funatsu H, Kato H. Results of lung cancer screening programs in Japan: early detection and localisation of lung tumours in high risk groups. In: Band, PR, editor. Early detection and localisation of lung tumours in high risk groups. Recent results of cancer research series. Vol. 82, 179-186. Springer-Verlag, Heidelberg, Germany, 1982.
21. Nash FA, Morgan JM, Tomkins JG. South London Lung Cancer Study. Br Med J 1968; 2: 715-21.
22. Anon. Lung cancer detection by chest x-rays at 6 monthly intervals. Nova Scotia Med Bull 1970; 49: 14-5.
23. Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23: 414-20.
24. Brett GZ. The presymptomatic diagnosis of lung cancer. Proc R Soc Med 1966; 59: 1208-14.
25. Brett GZ. Earlier diagnosis and survival in lung cancer. Br Med J 1969; 4: 260-2.
26. Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J 1989; 2: 656-62.
27. Wilde J, Sr., Durschmied H, Dubitzky J, et al. [Effectiveness of photofluorography screening studies in the early detection of bronchial carcinoma]. Z Erkr Atmungsorgane 1983; 160: 128-41.
28. Baker RR, Tockman MS, Marsh BR, et al. Screening for bronchogenic carcinoma: the surgical experience. J Thorac Cardiovasc Surg 1979; 78: 876-82.
29. Frost JK, Ball WC, Jr., Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984; 130: 549-54.
30. Levin ML, Tockman MS, Frost JK, Ball WC, Jr. Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: a preliminary report. Recent Results Cancer Res 1982; 82: 138-46.
31. Stitik FP, Tockman MS. Radiographic screening in the early detection of lung cancer. Radiol Clin North Am 1978; 16: 347-66.
32. Tockman MS, Frost JK, Stitik FP, Levin ML, Ball WC, Marsh BR. Screening and detection of lung cancer. In: J. Aisner editor. Lung Cancer. 25-36. Churchill Livingstone, New York, USA, 1985.
33. Tockman MS. Survival and mortality from lung cancer in a screened population. Chest 1986; 89 (Suppl.): 324-5.
34. Flehinger BJ, Kimmel M. The natural history of lung cancer in a periodically screened population. Biometrics 1987; 43: 127-44.
35. Flehinger BJ, Melamed MR. Current status of screening for lung cancer. Chest Surg Clin N Am 1994; 4: 1-15.
36. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. Am Rev Respir Dis 1984; 130: 555-60.
37. Heelan RT, Flehinger BJ, Melamed MR, et al. Non-small-cell lung cancer: results of the New York screening program. Radiology 1984; 151: 289-93.
38. Martini N. Results of the Memorial Sloan-Kettering study in screening for early lung cancer. Chest 1986; 89 (Suppl 4): 325.
39. Melamed M, Flehinger B, Miller D, et al. Preliminary report of the lung cancer detection program in New York. Cancer 1977; 39: 369-82.
40. Melamed MR, Flehinger BJ, Zaman MB. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am 1987; 67: 909-24.
41. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984; 86: 44-53.
42. Flehinger BJ, Kimmel M, Polyak T, Melamed MR. Screening for lung cancer. The Mayo Lung Project revisited. Cancer 1993; 72: 1573-80.
43. Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67: 1155-64.
44. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 1984; 130: 561-5.
45. Fontana RS, Sanderson DR, Woolner LB, et al. The Mayo lung project for early detection and localization of bronchogenic carcinoma: a status report. Chest 1975; 67: 511-22.
46. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. J Occup Med 1986; 28: 746-50.
47. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92: 1308-16.
48. Marcus PM, Prorok PC. Reanalysis of the Mayo Lung Project data: the impact of confounding and effect modification. J Med Screen 1999; 6: 47-9.
49. Muhm JR, Miller WE, Fontana RS, Sanderson DR, Uhlenhopp MA. Lung cancer detected during a screening program using four-month chest radiographs. Radiology 1983; 148: 609-15.
50. Sanderson D, Fontana R. Results of Mayo lung project: an interim report. Recent Results Cancer Res 1982; 82: 179-86.
51. Sanderson DR. Lung cancer screening. The Mayo Study. Chest 1986; 89 (Suppl. 4): 324.
52. Taylor WF, Fontana RS. Biometric design of the Mayo Lung Project for early detection and localization of bronchogenic carcinoma. Cancer 1972; 30: 1344-7.
53. Taylor WF, Fontana RS, Uhlenhopp MA, Davis CS. Some results of screening for early lung cancer. Cancer 1981; 47: 1114-20.
54. Woolner LB, Fontana RS, Cortese DA, et al. Roentgenographically occult lung cancer: pathologic findings and frequency of multicentricity during a 10-year period. Mayo Clin Proc 1984; 59: 453-66.
55. Woolner LB, Fontana RS, Sanderson DR, et al. Mayo Lung Project: evaluation of lung cancer screening through December 1979. Mayo Clin Proc 1981; 56: 544-55.
56. Kubik AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer 2000; 89: 2363-8.
57. Kubik A. [Risk groups and effective x-ray screening frequency of bronchial cancer]. Z Erkr Atmungsorgane 1983; 160: 18-25.
58. Kubik A, Haerting J. Survival and mortality in a randomized study of lung cancer detection. Neoplasma 1990; 37: 467-75.
59. Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45: 26-33.
60. Kubik A, Polak J. Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. Cancer 1986; 57: 2427-37.
61. Walter SD, Kubik A, Parkin DM, Reissigova J, Adamec M, Khlat M. The natural history of lung cancer estimated from the results of a randomized trial of screening. Cancer Causes Control 1992; 3: 115-23.
62. Rossi A, Maione P, Colantuoni G, et al. Screening for lung cancer: New horizons? Crit Rev Oncol Hematol 2005; 56: 311-20.
63. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21: 273S-309S.
64. NRCP. Ionizing Radiation exposures of the population of the United States. Report no. 93. National Council on Radiation Protection and Measurements, Washington, DC, USA, 1987.
65. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
66. Henschke CI. Early lung cancer action project: overall design and findings from baseline screening. Cancer 2000; 89: 2474-82.
67. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: a summary of the findings on baseline screening. Oncologist 2001; 6: 147-52.
68. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screenings. Cancer 2001; 92: 153-9.
69. Badwe RA. Re: Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2001; 93: 321-3.
70. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO, Allen KL. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235(1): 259-65.
71. Fontana RS. The Mayo Lung Project: a perspective. Cancer 2000; 89: 2352-5.
72. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355: 1763-71.
73. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 2007; 297: 953-61.
74. http://www.cancer.gov/clinicaltrials/NCI-NLST.
75. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120: 868-74.
76. Flake GP, Rivera MP, Funkhouser WK, et al. Detection of pre-invasive lung cancer: technical aspects of the LIFE project. Toxicol Pathol 2007; 35: 65-74.
77. Carpagnano GE, Spanevello A, Curci C, et al. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol Res 2007; 16: 375-81.
78. Castagnaro A, Marangio E, Verduri A, et al. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp Lung Res 2007; 33: 289-301.
79. Kettunen E, Salmenkivi K, Vuopala K, et al. Copy number gains on 5p15, 6p11-q11, 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer. Lung Cancer 2006; 54: 169-76.
80. Li R, Todd NW, Qiu Q, et al. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin Cancer Res 2007; 13: 482-7.
81. Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill HJ. Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem 1985; 31: 1278-82.
82. Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999; 353: 1930-3.
83. Poli D, Carbognani P, Corradi M, et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005; 6: 71.
84. Chen X, Xu F, Wang Y, et al. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer 2007; 110: 835-44.
85. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr 2007; 21: 553-66.
86. Mazzone PJ, Hammel J, Dweik R, et al. Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax 2007; 62: 565-8.
87. Munoz BC, Steinthal G, Sunshine S. Conductive polymer-carbon black composites-based sensor arrays for use in a electronic nose. Sensor Rev 1999; 19: 300-5.
88. Di Natale C, Macagnano A, Martinelli E, et al. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron 2003; 18: 1209-18.
89. Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 2005; 171: 1286-91.
90. McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr Cancer Ther 2006; 5: 30-9.
91. Hunt J. Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease. J Allergy Clin Immunol 2002; 110: 28-34.
92. Carpagnano GE, Resta O, Foschino-Barbaro MP, Gramiccioni E, Carpagnano F. Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers 2002; 17: 141-5.
93. Carpagnano GE, Foschino-Barbaro MP, Resta O, Gramiccioni E, Carpagnano F. Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology 2004; 66: 180-4.
94. Gessner C, Kuhn H, Toepfer K, Hammerschmidt S, Schauer J, Wirtz H. Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. Lung Cancer 2004; 43: 215-22.
95. Carpagnano GE, Foschino-Barbaro MP, Spanevello A, et al. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Am J Respir Crit Care Med 2008; 177: 337-41.
96. Carpagnano GE, Foschino-Barbaro MP, Mule G, et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med 2005; 172: 738-44.
97. Moller P, Folkmann JK, Forchhammer L, Bräuner EV, Danielsen PH, Risom L, Loft S. Air pollution, oxidative damage to DNA, and carcinogenesis. Cancer Lett 2008; 24; [Epub ahead of print].
98. Wewel AR, Crusius JA, Gatzemeier U, Heckmayr M, Becher G, Magnussen H, Jörres RA, Holz O. Time course of exhaled hydrogen peroxide and nitric oxide during chemotherapy. Eur Respir J 2006; 27: 1033-9.
99. Yildiz PB, Shyr Y, Rahman JS, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007; 2: 893-901.
100. Gao WM, Kuick R, Orchekowski RP, et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005; 5: 110.
101. Mutti A, Corradi M, Goldoni M, Vettori MV, Bernard A, Apostoli P. Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma. Chest 2006;129:1288-97.
102. Gierada DS, Pilgram TK, Ford M, et al. Lung cancer: Interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. Radiology 2008; 246: 265-72.
103. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991